ZLMT-12
ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active CDK2/9 inhibitor with IC50 values of 0.002 and 0.011 μM for CDK9 and CDK2, respectively. ZLMT-12 has a weak inhibitory effect on AChE (IC50=19.023 μM) and BChE (IC50=2.768 μM) . ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase[1].
Product Specifications
CAS Number
2841473-39-8
UNSPSC
12352005
Target
Apoptosis; CDK; Cholinesterase (ChE)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Neuronal Signaling
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zlmt-12.html
Solubility
10 mM in DMSO
Smiles
O=C(C1CC1)NC2=NC=CC(C3=CC=C4N=C5C(CCCCC5)=C(N6C[C@@H](N)CC6)C4=C3)=N2.[H]Cl
Molecular Formula
C26H31ClN6O
Molecular Weight
479.02
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
AChE; BChE; CDK2; CDK9
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![CRISP3 Mouse Monoclonal Antibody [Clone ID: LV-2A2]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
Golgi Complex (371-4), CF405S conjugate, 0.1mg/mL
ASB3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
